Skip to main content

PAPEL DE LAS ADIPOKINAS EN LA DEGENERACION DEL DISCO INTERVERTEBRAL (DDIV): UN NUEVO ENFOQUE FISIOPATOLOGICO.

PI17/00409

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
Execution centre INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA (IDIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

  • Aragón Herrera, Alana
  • Otero-Santiago, Manuel
  • Anido Varela, Laura
  • Moraña Fernández, Sandra
  • Campos-Toimil, Manuel
  • García-Caballero, Tomás
  • Barral, Luis
  • Tarazón, Estefanía
  • Roselló-Lletí, Esther
  • Portolés, Manuel
  • Gualillo, Oreste
  • Moscoso, Isabel
  • Lage Fernández, Ricardo
  • González-Juanatey, José Ramón
  • Feijóo-Bandín, Sandra
  • Lago, Francisca
[Abstract] The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and cardiovascular disease. Recent evidences have shown the benefits of the SGLT2 inhibitor empagliflozin on improving liver steatosis and fibrosis in patients with T2DM. Metabolomic studies have been shown to be very useful to improve the understanding of liver pathophysiology during the development and progression of metabolic hepatic diseases, and because the effects of empagliflozin and of other SGLT2 inhibitors on the complete metabolic profile of the liver has never been analysed before, we decided to study the impact on the liver of male Zucker diabetic fatty (ZDF) rats of a treatment for 6 weeks with empagliflozin using an untargeted metabolomics approach, with the purpose to help to clarify the benefits of the use of empagliflozin at hepatic level. We found that empagliflozin is able to change the hepatic lipidome towards a protective profile, through an increase of monounsaturated and polyunsaturated glycerides, phosphatidylcholines, phosphatidylethanolamines, lysophosphatidylinositols and lysophosphatidylcholines. Empagliflozin also induces a decrease in the levels of the markers of inflammation IL-6, chemerin and chemerin receptor in the liver. Our results provide new evidences regarding the molecular pathways through which empagliflozin could exert hepatoprotector beneficial effects in T2DM., This work was supported by Boehringer Ingelheim Pharma GmbH and Co., by the National Institute of Health “Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III” Madrid, Spain (PI15/00681, PI17/00409, PI18/00821, PI20/00902, RETICS Programme RD16/0012/0014 and CIBER de Enfermedades Cardiovasculares (CIBERCV)); European Regional Development Fund (FEDER) and European Union framework MSCA-RISE-H2020 Programme (Project number 734899). AH-A was funded by predoctoral research grants from Xunta de Galicia and FPU Program of the Spanish Ministry of Science, Innovation and Universities (Spain); MF-S was funded by the predoctoral research grants “Programa Científico do Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CiMUS) (Spain) and Xunta de Galicia; and AV-L was funded by the predoctoral research grant from the PFIS Program of the Spanish Ministry of Science and Instituto de Salud Carlos III (Spain)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

  • Batista-Liz, Joao Carlos
  • Genre, Fernanda
  • Pulito-Cueto, Verónica
  • Remuzgo-Martínez, Sara
  • Prieto-Peña, Diana
  • Márquez, Ana
  • Ortego-Centeno, Norberto
  • Leonardo, María Teresa
  • Peñalba, Ana
  • Narváez, Javier
  • Martín-Penagos, Luis
  • Belmar-Vega, Lara
  • Gómez Fernández, Cristina
  • Miranda-Filloy, J. A.
  • Caminal-Montero, Luis
  • Collado, Paz
  • Árgila, Diego de
  • Quiroga, Patricia
  • Vicente, Esther
  • Triguero-Martínez, Ana
  • Rubio, Esteban
  • León Luque, Manuel
  • Blanco-Madrigal, Juan María
  • Galíndez-Agirregoikoa, E.
  • Martín, Javier
  • Gualillo, Oreste
  • Blanco, Ricardo
  • Castañeda, Santos
  • González-Gay, Miguel A.
  • López-Mejías, Raquel
CD40, BLK and BANK1 genes involved in the development and signaling of B-cells are identified as susceptibility loci for numerous inflammatory diseases. Accordingly, we assessed the potential influence of CD40, BLK and BANK1 on the pathogenesis of immunoglobulin-A vasculitis (IgAV), predominantly a B-lymphocyte inflammatory condition. Three genetic variants within CD40 (rs1883832, rs1535045, rs4813003) and BLK (rs2254546, rs2736340, rs2618476) as well as two BANK1 polymorphisms (rs10516487, rs3733197), previously associated with inflammatory diseases, were genotyped in 382 Caucasian patients with IgAV and 955 sex- and ethnically matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of CD40, BLK and BANK1 when IgAV patients and healthy controls were compared. Similar results were found when CD40, BLK and BANK1 genotypes or alleles frequencies were compared between patients with IgAV stratified according to the age at disease onset or to the presence/absence of gastrointestinal or renal manifestations. Moreover, no CD40, BLK and BANK1 haplotype differences were disclosed between patients with IgAV and healthy controls and between patients with IgAV stratified according to the clinical characteristics mentioned above. Our findings indicate that CD40, BLK and BANK1 do not contribute to the genetic background of IgAV., This study was supported by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” (grants PI18/00042 and PI21/00042) from “Instituto de Salud Carlos III” (ISCIII, Health Ministry, Spain). D.P.-P. is a recipient of a Río Hortega program fellowship from the ISCIII, co-funded by the European Social Fund (ESF, “Investing in your future”) (grant number CM20/00006). F.G. is supported by funds of the RICORS Program from ISCIII, co-funded by the European Union (grant number RD21/0002/0025). V.P.-C. is supported by funds of PI18/00042. S.R.-M. is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, co-funded by the European Regional Development Fund (ERDF)). O.G. is a staff member of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (grant numbers RD16/0012/0014 (RIER) and PI17/00409). He is a beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Program, project 734899—Olive-Net. R.L.-M. is a recipient of a Miguel Servet type II program fellowship from the ISCIII, co-funded by ESF (“Investing in your future”) (grant number CPII21/00004)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Influence of MUC5B gene on antisynthetase syndrome

  • López-Mejías, Raquel|||0000-0003-0548-2689
  • Remuzgo-Martínez, Sara|||0000-0003-4455-7241
  • Genre, Fernanda|||0000-0003-3612-1448
  • Pulito-Cueto, Verónica|||0000-0002-3534-8467
  • Fernández Rozas, Sonia María
  • Llorca, Javier|||0000-0001-8569-861X
  • Iturbe, David|||0000-0002-5241-266X
  • Mora Cuesta, Víctor Manuel|||0000-0002-8161-0462
  • Ortego-Centeno, Norberto|||0000-0003-2325-0937
  • Gómez, Nair Pérez
  • Mera-Varela, Antonio
  • Martínez Barrio, Julia
  • López Longo, Francisco Javier
  • Mijares, Verónica
  • Lera-Gómez, Leticia
  • Usetti, María Piedad
  • Laporta, Rosalía
  • Pérez González, Virginia Luz
  • Gafas, Alicia De Pablo
  • Alfranca González, María Aránzazu
  • Calvo Alén, Jaime|||0000-0001-9378-8412
  • Romero-Bueno, Fredeswinda
  • Sánchez Pernaute, Olga
  • Nuno, Laura
  • Bonilla, Gema
  • Balsa, Alejandro|||0000-0001-8070-7062
  • Hernández-González, Fernanda
  • Grafia, Ignacio
  • Prieto-González, Sergio|||0000-0003-3179-597X
  • Narváez, Javier|||0000-0002-1614-8064
  • Trallero Araguás, Ernesto|||0000-0003-3365-4521
  • Selva O'Callaghan, Albert|||0000-0003-2823-9761
  • Gualillo, Oreste|||0000-0002-7154-1328
  • Castañeda, Santos|||0000-0002-7748-853X
  • Cavagna, Lorenzo|||0000-0003-3292-1528
  • Cifrián, José Manuel|||0000-0003-3682-0142
  • Gonzalez-Gay, MA.|||0000-0002-7924-7406
MUC5B rs35705950 (G/T) is strongly associated with idiopathic pulmonary fibrosis (IPF) and also contributes to the risk of interstitial lung disease (ILD) in rheumatoid arthritis (RA-ILD) and chronic hypersensitivity pneumonitis (CHP). Due to this, we evaluated the implication of MUC5B rs35705950 in antisynthetase syndrome (ASSD), a pathology characterised by a high ILD incidence. 160 patients with ASSD (142 with ILD associated with ASSD [ASSD-ILD+]), 232 with ILD unrelated to ASSD (comprising 161 IPF, 27 RA-ILD and 44 CHP) and 534 healthy controls were genotyped. MUC5B rs35705950 frequency did not significantly differ between ASSD-ILD+ patients and healthy controls nor when ASSD patients were stratified according to the presence/absence of anti Jo-1 antibodies or ILD. No significant differences in MUC5B rs35705950 were also observed in ASSD-ILD+ patients with a usual interstitial pneumonia (UIP) pattern when compared to those with a non-UIP pattern. However, a statistically significant decrease of MUC5B rs35705950 GT, TT and T frequencies in ASSD-ILD+ patients compared to patients with ILD unrelated to ASSD was observed. In summary, our study does not support a role of MUC5B rs35705950 in ASSD. It also indicates that there are genetic differences between ILD associated with and that unrelated to ASSD.